Loading clinical trials...

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2) | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)

A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat in Non-Obese Subjects

NCT02398188•Evofem Inc.

View on ClinicalTrials.gov

Summary

This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Healthy male or non-pregnant female subjects
•Capable of providing written consent.
•BMI \< 30 kg/m2
•Stable diet and exercise routine
•Central abdominal bulging that is evaluated by the clinician at least slight bulge, not flat

Exclusion Criteria

•Have had any treatment of the fat around your abdomen, including surgical procedures (tummy tuck, liposuction), injections for fat loss or treatments with devices to reduce fat in your abdomen.
•Plan on starting a weight loss or exercise program during the study.
•Known hypersensitivity to study drugs

Locations (35)

Total Skin and Beauty Dermatology Center

Birmingham, Alabama, United States

Stoll Dermatology of Beverly Hills

Beverly Hills, California, United States

Diagnamics, Inc.

Encinitas, California, United States

Ablon Skin Institute And Research Center

Manhattan Beach, California, United States

Dermatology Specialists, Inc.

Oceanside, California, United States

Rancho Mirage Dermatology

Rancho Mirage, California, United States

Faces Plus

San Diego, California, United States

Therapeutics Clinical Research

San Diego, California, United States

Syrentis Clinical Research

Santa Ana, California, United States

Colorado Medical Research Center

Denver, Colorado, United States

Key Dates

Start Date

April 9, 2015

Primary Completion Date

October 29, 2015

Completion Date

October 29, 2015

Last Updated

January 7, 2019

Enrollment

793

ACTUAL participants

Conditions

Central Abdominal Bulging

Interventions

LIPO-202

DRUG

Placebo

DRUG